Table 2.

a. Predicting aGvHD grade II-IV. Variables in this model were selected from age, race, sex, disease, conditioning, KPS, HCT-CI, and donor type; significant level for entry = 0.1 and significant level for stay = 0.2, other variables are forced in the model (N = 80, event = 53). b. Predicting cGvHD. Variables in this model were selected from age, race, sex, disease, conditioning, KPS, HCT-CI, and donor type; significant level for entry = 0.1 and significant level for stay = 0.2, other variables are forced in the model, i.e. none candidate variable was selected (N = 80, event = 35).

A
	OR (95% CI)	P-Value	Overall P-Value
Group
No Hepatic Steatosis	-REF-		0.90
Hepatic Steatosis	0.92 (0.24–3.57)	0.90
Pre-transplant weight (kg)
Continuous	1.05 (0.90–1.21)	0.54	0.53
Height (cm)
Continuous	1.01 (0.92–1.12)	0.78	0.77
Subcutaneous fat at L3
Continuous	0.99 (0.98–1.01)	0.33	0.32
Visceral fat at L3
Continuous	1.00 (0.99–1.01)	0.40	0.40
Skeletal muscle at L3
Continuous	1.01 (0.97–1.04)	0.69	0.69
Race
White	-REF-		0.08
Other	0.27 (0.06–1.20)	0.09
Post-transplant cyclophosphamide
No	-REF-		<0.001
Yes	0.07 (0.01–0.36)	0.001
Donor Type
Related	-REF-		0.03
Unrelated	3.57 (1.11–11.47)	0.03
B
Group
No Hepatic Steatosis	-REF-
Hepatic Steatosis	4.19 (1.11–15.75)	0.03
Pre-transplant weight (kg)
Continuous	0.99 (0.88–1.10)	0.80
Height (cm)
Continuous	0.95 (0.87–1.05)	0.31
Subcutaneous fat
Continuous	1.00 (0.99–1.01)	0.53
Visceral fat
Continuous	1.00 (0.99–1.01)	0.90
Skeletal muscle
Continuous	1.01 (0.98–1.04)	0.45
Disease
MPS/MPN/Other	-REF-
Acute Leukemia	17.17 (1.26–233.70)	0.03
Lymphomas	1.17 (0.37–3.75)	0.79

MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm